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Influence	on	WHO	recommendations	
The	results	of	the	WHO	guideline	evaluation	were	presented	to	a	cross-
departmental	meeting	of	the	WHO	in	Geneva	in	November	2012.	Informal	feedback	
from	the	GRC	credits	the	paper	with	helping	to	strengthen	the	commitment	of	the	
organization	to	the	improved	standards,	and	reinforcing	the	authority	of	the	GRC.	
The	findings	of	the	Ghana	paper	were	presented	at	a	WHO	meeting	of	the	Essential	
Medicines	for	Children	Project	(November	2011),	and	at	the	Cochrane	Colloquium	
in	Hyderabad	(September	2014).	This	paper	highlights	the	importance	of	national	
debate	of	the	evidence-base	and	implications	of	policy	change,	prior	to	adopting	
and	implementing	global	recommendations,	and	fits	within	a	broader	discussion	of	
the	importance	of	documenting	the	steps	between	evidence	and	decisions.		
The	GRADE	working	group	(through	an	extension	project	known	as	DECIDE:	
Developing	and	Evaluating	Communication	strategies	to	support	Informed	
Decisions	and	practice	based	on	Evidence),	has	now	developed	worksheets	for	use	
by	guideline	panels,	to	formally	document	the	evidence	and	debate	around	each	of	
the	different	factors	influencing	a	decision:	size	of	the	problem,	benefits	and	harms	
of	the	intervention,	costs,	feasibility,	acceptability	etc.	[75].		
In	the	third	edition	of	the	WHO	Malaria	Treatment	Guidelines	we	included	a	
simplified	version	of	this	worksheet	(which	captured	some	of	the	important	factors	
influencing	the	decisions)	but	the	panel	did	not	openly	discuss	each	of	the	
considerations	in	a	step-wise	fashion	as	advocated	by	the	GRADE	group	[14].	
Although	the	current	textbook	format	of	the	Malaria	Treatment	Guidelines	seems	
popular	with	end	users	(it	is	a	bestseller	among	WHO	documents),	future	editions	
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might	better	serve	the	information	needs	of	malaria	programme	managers	if	they	
utilized	this	worksheet	approach	to	clearly	document	the	rationale,	evidence,	and	
debate	around	each	major	recommendation.	
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Chapter	6.	Conclusions	
This	PhD	presents	a	case	study	of	an	academic	group	working	as	info-mediaries	at	
the	interface	between	research	and	global	policy,	and	at	the	interface	between	
global	policy	and	national	decisions:	advising	on	methodological	issues,	conducting	
systematic	evidence	reviews	in	response	to	information	needs,	and	developing	
approaches	to	reinterpret	reviews	for	national	decision-making.	
It	contains	one	of	the	very	few	formal	evaluations	of	policy	making	within	the	WHO,	
and	the	first	published	demonstration	of	evidence-based,	rigorous,	processes	being	
used	to	re-assess	global	recommendations	for	a	specific	low-income	setting.	The	
included	systematic	reviews	facilitated	new,	transparent,	global	recommendations	
for	dihydroartemisinin-piperaquine	as	a	first	line	therapy	for	uncomplicated	
malaria,	and	intravenous	artesunate	as	first-line	treatment	for	severe	malaria.		
The	scientific	contribution	of	this	work	
This	PhD	contributed	extensively,	particularly	in	the	field	of	malaria,	to	improved	
presentation	and	interpretation	of	systematic	review	results,	and	subsequently	to	
improved	transparency	in	global	and	national	level	recommendations.	The	included	
systematic	reviews	helped	to	establish	the	credibility	of	meta-analysis	in	the	
malaria	field,	and	were	among	the	first	to	include	innovative	elements	such	as:	
GRADE	summary	of	findings	tables,	standardized	language	reflecting	the	level	of	
certainty	in	effect	estimates,	logic	frameworks,	and	brief	economic	summaries.	My	
experiences	contributed	to	the	broader	discussions	on	these	topics	and	to	further	
development	of	their	methods	[77][78][79].	
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The	first	edition	of	the	WHO	Malaria	Treatment	Guidelines	recommended	five	drug	
combinations	but	stated	only	that	these	‘had	achieved	the	target	of	95%	treatment	
success’.	There	was	little	guidance	on	how	to	choose	between	these	five	
combinations,	and	little	comment	on	any	potential	adverse	effects.	Furthermore	
there	were	clear	inconsistencies	in	the	reporting	of	trial	results	across	malaria	
research	groups,	making	direct	comparison	between	trials	impossible.	
My	early	work,	summarizing	trial	data	for	artemisinin-based	combinations,	built	on	
existing	protocols	to	develop	a	standard	set	of	treatment	outcomes	(including	
adverse	effects),	and	a	standardized	approach	to	trial	analysis	that	fully	considered	
the	potential	effects	of	missing	data	on	the	primary	efficacy	outcomes.	These	were	
essential	for	the	credibility	of	meta-analysis	across	anti-malarial	drug	trials,	and	are	
now	standard	for	Cochrane	reviews	of	artemisinin-based	combination	therapies.	
To	facilitate	informed	national	drug	selection,	we	also	needed	to	provide	clear	
summaries	of	the	comparative	safety	of	the	main	ACTs.	We	therefore	developed	a	
system	for	assessing	the	completeness	of	adverse	event	monitoring	and	reporting,	
and	for	the	third	edition	of	the	malaria	treatment	guidelines	I	produced	detailed	
adverse	event	GRADE	profiles	for	each	ACT.		These	adverse	event	profiles	go	
beyond	any	current	guidance	of	either	Cochrane	or	the	GRADE	working	group,	and	
are	an	important	avenue	for	further	work.	Typically	health	staff	and	patients	
require	two	types	of	information	on	adverse	effects;	the	frequency	and	nature	of	
common	short	term	‘side-effects’:	for	which	there	is	now	a	reasonable	amount	of	
data	from	RCTs	of	ACTs;	and	the	risk	of	rare	but	serious	adverse	effects:	for	which	
RCTs	are	unlikely	to	be	sufficient.	In	a	forthcoming	review	of	mefloquine	to	prevent	
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malaria	in	travellers	we	have	further	developed	these	methods	to	incorporate	large	
amounts	of	data	from	non-randomized	studies	to	try	and	capture	data	on	rare	
effects	[80]	
My	work	in	Ghana	highlighted	the	importance	of	being	explicit	about	the	
applicability	of	systematic	review	results	if	they	are	to	be	truly	useful	to	decision-
makers	in	different	settings.	This	is	particularly	important	in	infectious	diseases	
where	resistance	(and	consequently	efficacy)	vary	with	time	and	place,	and	
geographical	presentations	of	data	were	essential	to	generating	confidence	among	
the	Ghana	national	guideline	panel.	Cochrane	methods	at	the	time	only	
recommended	sub-group	analysis	as	part	of	the	assessment	of	heterogeneity,	and	
applicability	was	usually	only	considered	informally	in	the	discussion.	To	improve	
this,	and	to	facilitate	decision	making	at	global	and	national	levels,	I	incorporated	
the	time	and	place	of	the	primary	trials	into	all	forest	plots,	and	conducted	sub-
group	analysis	against	a	pre-defined	set	of	applicability	criteria	regardless	of	the	
presence	or	absence	of	heterogeneity.	My	approach	was	developed	independently	
of	the	GRADE	working	group,	but	has	subsequently	been	recommended	as	part	of	
the	assessment	of	‘directness’	[81].		
Prior	to	the	development	of	the	GRADE	approach	to	assessing	the	quality	of	
evidence,	it	was	commonplace	for	the	conclusions	of	Cochrane	reviews	to	be	based	
solely	on	the	statistical	significance	of	the	primary	outcomes,	and	early	users	of	the	
GRADE	approach	often	saw	it	simply	as	an	additional	step	at	the	end	of	a	review.	
However,	the	real	value	of	the	GRADE	approach	is	its	ability	to	pull	together	all	the	
elements	of	a	Cochrane	review,	into	a	reliable	conclusion	that	fully	considers	the	
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risk	of	bias	of	the	trials,	the	characteristics	and	applicability	of	the	trials,	and	the	
statistical	certainty	in	the	results.	As	such,	applying	the	GRADE	approach	is	an	
integral	part	of	structuring	the	analysis,	writing	the	results,	and	drawing	
conclusions.	This	PhD	includes	the	first	two	reviews	by	the	Cochrane	Infectious	
Diseases	Group	to	contain	GRADE	summary	of	findings	tables,	and	these	reviews	
were	instrumental	in	establishing	these	processes	within	the	Cochrane	Infectious	
Diseases	group,	for	pushing	their	adoption	wider	in	the	collaboration,	and	for	
establishing	the	GRADE	approach	within	the	WHO	Malaria	Treatment	Guidelines.		
Alongside	the	adoption	of	GRADE,	these	reviews	also	pioneered	the	use	of	
standardized	wording	of	results,	especially	within	the	abstract	and	plain	language	
summaries	[82].	This	wording	was	developed	by	researchers	from	the	Cochrane	
EPOC	group,	and	aims	to	reflect	the	size	of	the	observed	effects	AND	the	overall	
confidence	that	this	effect	is	real	(the	GRADE	quality	of	the	evidence).	This	
innovation,	combined	with	the	formal	applicability	assessment,	and	GRADE	
assessment	of	the	quality	of	evidence,	combined	to	facilitate	transparent	and	
reliable	statements	about	the	results	of	systematic	reviews.	Subsequent	WHO	
recommendations	based	on	these	reviews	have	also	incorporated	language	
reflecting	both	the	estimated	magnitude	of	effects	and	the	certainty	in	these	
effects.		
Logic	frameworks	are	a	more	recent	addition	to	systematic	reviews,	which	require	
authors	to	think	critically	about	the	assumptions	underlying	a	research	question.	
They	can	be	used	to	clarify	the	proposed	mechanism	of	action	of	an	intervention,	
and	distinguish	the	important	impact	outcomes	from	the	intermediate	process	
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outcomes.	They	can	highlight	deficiencies	in	the	outcomes	being	measured	and	
reported	in	the	existing	trials,	and	contribute	to	improved	understanding.	The	logic	
framework	presented	within	this	PhD	helped	to	clarify	where	the	potential	benefits	
and	harms	of	introducing	RDTs	lay	(in	those	testing	negative),	and	in	what	
epidemiological	settings	the	benefits	and	risks	would	be	greatest.	These	insights	
had	not	been	clearly	articulated	in	any	policy	documents	at	the	time.	As	reviews	
begin	to	tackle	more	complex	questions,	logic	frameworks	are	likely	to	become	
increasingly	common	and	play	an	important	role	in	developing	the	question	and	
framing	the	interpretation.	During	the	course	of	this	PhD,	I	have	worked	with	
multiple	authorship	teams	to	develop	logic	frameworks	for	their	own	topic,	often	
leading	to	radical	restructuring	of	the	analyses	and	reframing	of	the	review	
conclusions.	These	reviews	have	helped	to	establish	logic	frameworks	within	the	
Cochrane	Infectious	Diseases	Group,	and	to	promote	their	use	wider	in	the	
collaboration.	
Cost	and	cost-effectiveness	are	usually	not	included	within	Cochrane	systematic	
reviews,	and	this	is	probably	appropriate	as	cost	only	becomes	relevant	once	the	
efficacy	and	safety	of	an	intervention	have	been	established.	Cost	considerations	
are	also	rarely	(or	only	briefly)	included	in	WHO	guidelines	(probably	due	to	rapid	
changes	and	variability	in	pricing).	The	evidence	for	the	clinical	superiority	of	
artesunate	in	severe	malaria	was	however	so	overwhelming	that	cost	(and	supply)	
became	the	primary	concern	for	national	policy-makers	following	the	WHO	
recommendation.	For	this	reason	I	supervised	the	inclusion	of	a	brief	summary	of	
economic	data	in	the	most	recent	update	of	this	review	(which	equates	to	a	very	
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rapid	second	systematic	review	of	cost-effectiveness	data).	This	remains	one	of	the	
few	examples	of	this	methodology,	but	a	valuable	addition	to	this	review.		
The	developing	role	for	academics	at	the	interface	between	research	and	policy	
For	many	years,	‘getting	research	into	policy	and	practice’	was	an	elusive	and	
frustrating	problem	for	the	research	community,	but	over	the	last	20	years	
evidence	synthesis	has	grown	and	developed	to	fill	the	research-to-policy	gap.	
Subsequently,	the	development	of	the	GRADE	approach	has	provided	a	useable	
structure	for	converting	systematic	review	findings	into	transparent,	informed	
decisions.	
To	facilitate	and	strengthen	the	use	of	these	methods,	academic	input	is	now	
required	at	all	stages	of	the	guideline	process,	particularly	where	panels	are	heavily	
weighted	with	clinicians,	or	lack	sufficient	experience	in	research	synthesis.	It	is	
recognized	that	such	groups	may	struggle	to	formulate	clearly	answerable	
questions,	and	identify	where	and	how	evidence	synthesis	may	help	[66][76].			
Most	guideline	development	manuals	now	recommend	a	‘methodologist’	as	part	of	
a	guideline	panel,	but	very	little	has	been	written	about	the	required	competencies.	
The	WHO	guideline	for	guidelines	state	simply	that	the	methodologist	should	be	‘an	
expert	in	guideline	development	processes’	[66],	and	writing	in	the	Lancet	
prominent	members	of	the	GRADE	working	group	wrote	that	methodologists	
should	have	‘advanced	training	(usually	Masters	or	PhD)	in	clinical	epidemiology,	
and	extensive	experience	in	the	interpretation,	and	usually	the	generation,	of	new	
knowledge	from	clinical	research’	[83].	
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The	GRADE	and	DECIDE	methodologies,	though	logically	structured,	are	not	
straightforward	and	their	useful	application	requires	experience,	and	usually	
innovation	to	adapt	them	to	the	specific	circumstance.	To	achieve	this,	guideline	
methodologists	usually	require	not	only	the	obvious	experience	in	evidence	
synthesis	and	the	GRADE	approach,	but	also	a	diverse	group	of	skills	such	as	group	
facilitation,	consensus	building,	and	plain	language	writing.	
The	systematic	reviews	presented	within	this	PhD	were	primarily	developed	to	
contribute	to	the	development	of	the	WHO	Malaria	Treatment	Guidelines,	but	are	
equally	relevant	to	national	policy	decisions.	Consequently,	a	core	requirement	for	
national	policy	groups,	if	unnecessary	duplication	is	to	be	avoided,	will	be	the	ability	
to	reinterpret	or	adapt	systematic	reviews	developed	outside	of	their	own	guideline	
process.	As	in	my	work	in	Ghana,	this	may	involve	an	appraisal	of	the	systematic	
review	methods,	re-analysis	and	structuring	of	the	systematic	review	data	to	match	
the	local	question,	and	where	necessary	a	rapid	update	of	the	review.		
Our	experience	as	info-mediaries	
When	the	guideline	process	works	well,	evidence	synthesis	can	facilitate	discussion	
among	the	guideline	panel,	increase	confidence	in	decisions,	and	improve	the	
reliability	and	clarity	of	recommendations.	Indeed	this	PhD	presents	some	good	
examples	of	high	quality	research,	synthesized	in	high	quality	reviews,	leading	to	
unchallenged	and	clear	decisions.	The	underlying	principles	of	both	GRADE	and	
DECIDE	are	simple	and	logical,	and	easily	taught	to	inexperienced	panels.	
Inevitably	however,	the	process	is	rarely	this	straightforward,	even	with	more	
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experienced	panels.	Without	adequate	input	from	those	making	the	decisions,	
systematic	reviews	can	easily	ask	the	wrong	question,	or	the	right	question	in	the	
wrong	way.	Similarly,	without	sufficient	content	and	methodological	expertise,	
systematic	reviews	can	simply	fail	to	produce	useable	information	rendering	them	
useless	and	frustrating	to	the	panel.		
More	commonly	though,	systematic	reviews	are	criticized	for	taking	too	long	to	
produce,	or	failing	to	reach	a	definitive	conclusion	due	to	the	low	quality	evidence	
available	(and	therefore	being	a	waste	of	time	compared	to	expert	opinion).	High	
quality	systematic	reviews	take	time	to	produce	(often	up	to	two	years	unless	there	
are	authors	with	large	amounts	of	dedicated	time),	and	real	and	imagined	time	
pressures	(or	industry	pressures)	can	cause	experts	to	push	for	practice	change	long	
before	benefits	or	harms	have	been	reliably	demonstrated	in	clinical	trials.		
Within	the	world	of	evidence	synthesis,	there	has	been	much	talk	about	the	need	
for	‘rapid	reviews’	to	ensure	that	evidence	synthesis	meets	policy	windows.	In	our	
experience	however,	guideline	development	is	rarely	an	emergency,	and	important	
questions	can	usually	be	predicted	in	advance,	through	frequent	dialogue	with	
policy	makers,	and	regular	literature	searches.	Over	three	editions	of	the	malaria	
treatment	guidelines,	the	long-term	engagement	between	the	Cochrane	Infectious	
Diseases	Group	and	the	WHO	Malaria	Treatment	Guidelines	committee	(and	
independent	funding	to	complete	policy-relevant	malaria	reviews),	facilitated	
timely	evidence	synthesis	in	anticipation	of,	and	response	to,	emerging	questions.		
While	more	linkages	such	as	this,	between	academic	groups	and	guideline	groups,	
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should	be	encouraged,	where	possible	the	evidence	synthesis	itself	should	probably	
remain	independent	of	the	committee.	Throughout	our	involvement	with	the	WHO	
Treatment	Guidelines	Committee	we	sought	input	for	the	questions	and	the	
outcomes	of	interest,	and	on	occasion	invited	panel	members	to	peer	referee	draft	
reviews.	However,	we	usually	resisted	involvement	of	panel	members	on	review	
teams	as	this	can	compromise	their	freedom	to	challenge	prevailing	opinions	in	
light	of	the	evidence,	and	conversely	the	freedom	of	the	committee	to	challenge	
the	conclusions	and	interpretation	of	the	systematic	review.		
Systematic	reviews	are	often	perceived	as	rigid	or	mechanical,	with	defined	
methods	leading	to	a	set	outcome.	In	reality	though,	while	the	core	methods	are	
now	well	established,	and	the	GRADE	approach	has	added	a	structure	for	
formulating	conclusions	from	results,	there	remains	a	great	deal	of	freedom	in	both	
the	presentation	and	interpretation	of	the	summarized	evidence.	It	is	therefore	
helpful	if	methodologists	have	some	oversight	of	the	multiple	systematic	reviews	
(from	multiple	academic	teams),	required	for	a	single	guideline.	For	both	the	
Malaria	Treatment	Guidelines,	and	the	Ghana	evidence	summaries,	my	oversight	
enabled	standardization	of	outcomes	and	approaches	across	reviews,	which	in	turn	
facilitated	understanding	and	interpretation	by	the	guideline	panels.	Furthermore,	
it	is	not	unusual	for	guideline	groups	to	ask	more	focused	questions	after	seeing	the	
synthesized	evidence,	and	it	is	useful	to	have	access	to	the	datasets	to	respond	
quickly	to	such	questions	from	the	panels.		
There	are	also	frequently	tensions	between	mechanistic	logic	and	demonstrable	
evidence,	particularly	when	the	quality	of	the	evidence	summarized	by	a	systematic	
Chapter	6									56	
	
review	is	perceived	as	low	quality.	Evidence	synthesis	may	be	discounted	for	
providing	a	weak	answer	that	pulls	against	established	logic,	or	a	weak	answer	
when	a	strong	message	is	wanted.	Indeed	it	is	not	unusual	for	guideline	groups	to	
express	a	desire	for	strong	clear	messages,	whatever	the	evidence,	for	fear	of	being	
ignored,	or	uncertainty	that	those	enacting	the	recommendations	will	have	the	
ability	to	interpret	the	evidence	appropriately.		
Our	experience	in	Ghana	however,	was	the	opposite	of	this,	with	the	panel	adding	a	
layer	of	interpretation	to	both	high	and	low	quality	evidence	which	may	be	easily	
missed	at	a	global	level.	With	some	training	and	facilitation,	the	panel	(dominated	
by	clinicians)	quickly	understood	the	magnitude	and	certainty	in	research	findings	in	
favor	of	artesunate	for	severe	malaria	but	made	insightful	judgments	about	
potential	difficulties	with	implementation	and	the	undesirable	consequences	of	
this.	Similarly,	despite	the	obvious	limitations	in	both	the	applicability	and	feasibility	
of	the	evidence	for	chlorhexidine,	they	could	see	the	problems	with	current	
practice	and	the	benefits	of	further	local	research.	Rather	than	weakening	global	
recommendations,	these	insights	fed	back	into,	and	improved,	global	guidance.		
It	is	important	to	note	however,	that	these	insights	into	national	conditions	in	
Ghana	were	usually	informal,	based	simply	on	the	experiences	of	the	panel,	rather	
than	reliable	data.	Although	we	routinely	searched	for	national	data,	even	when	it	
existed,	the	panel	had	little	confidence	in	its	validity,	at	times	choosing	to	trust	the	
results	of	studies	conducted	elsewhere	rather	than	their	own	routine	data	
collection.	The	composition	of	the	panel	is	therefore	instrumental	in	gaining	diverse	
opinions,	and	the	DECIDE	frameworks	(or	SUPPORT	tools	we	utilized)	at	least	
Chapter	6									57	
	
provide	a	transparent	and	structured	approach	for	considering	the	important	
factors.	
Preparing	global	guidelines	for	contextualization	at	national	level		
Moving	forward,	systematic	reviews	and	global	guidance	will	only	act	to	facilitate	
autonomous,	informed	decision-making	if	their	format	and	content	is	directly	
targeted	at	serving	the	information	needs	of	national	decision-makers.		
When	considering	the	evidence	of	effects	of	an	intervention,	there	is	a	need	for	
both	systematic	reviewers	and	guideline	groups	to	pre-specify	the	key	factors	that	
might	plausibly	influence	the	effects	in	a	given	population	or	setting;	to	adequately	
explore	this	effect;	and	to	clearly	present	the	findings	and	implications	[27][28][77].	
The	GRADE	criteria	of	consistency	and	directness	provide	a	framework	for	
considering	these	factors.		
Similarly,	for	complex	interventions	there	is	the	need	to	clearly	describe	all	facets	of	
the	interventions	with	the	potential	to	influence	the	outcome,	and	consider	the	
likelihood	that	real-life	(pragmatic)	interventions	will	really	achieve	these	aims.	As	
the	GRADE	approach	has	made	clear,	there	are	many	factors	that	influence	
decisions	beyond	evidence	of	effects.	The	GRADE/DECIDE	evidence-to-	decisions	
frameworks	go	some	way	to	increasing	the	transparency	of	these	additional	steps,	
by	presenting	both	the	evidence	and	debate	around	issues	such	as	cost	and	
feasibility.		
The	development	and	adoption	of	GRADE	summary	of	findings	tables,	and	DECIDE	
evidence-to-decision	frameworks,	has	radically	changed	the	format	and	content	of	
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WHO	guidelines.	Moving	forward	it	would	be	invaluable	to	garner	feedback	from	
the	target-users	of	guidelines	on	the	usefulness	of	this	information,	the	clarity	of	
their	presentation,	and	the	influence	on	subsequent	national	decisions.		
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